title: [Effect of eprex in therapy of anemia of nephrogenic genesis in patients with chronic renal failure concurrent with diabetic glomerulosclerosis before hemodialysis].
abstract: Data are submitted of results of treatment of anemia of nephrogenic genesis in 44 patients with diabetes mellitus complicated by diabetic glomerulosclerosis and chronic renal failure (CRF). In the patients, blood count was determined together with the corpuscular volume, blood serum level of creatinine, total protein, trace elements (calcium, sodium, potassium), total cholesterin, and beta-lipoproteins (beta-LP). Two drug regimens were adopted: 21 patient received iron preparations, folic acid, cyanocobalamin, calcium preparations, those preparations to be employed to reduce blood level of creatinine, antihypertensives, and eprex, 1000 u. four times daily for up to 4 weeks; these very preparations were given to 23 patients during the same time range but without eprex in the regimen. Four weeks later, those patients having taken eprex demonstrated significant (though not very high) elevation of the content of hemoglobin, corpuscular volume, erythrocytes and drop in total cholesterin and beta-LP in the blood serum. In those patients having had no eprex in their regimen, there were no changes in the studied parameters. Patients with diabetic glomerulosclerosis concurrent with CRF and nephrogenous anemia should be prescribed eprex and preparations of iron, folic acid, cyanocobalamin combined in correction of the above anemia even in the predialysis period. Iron preparations are not to be administered in those settings where there is no reduction in its level.
authors.forename: N A
authors.initials: NA
authors.lastname: Zueva
authors.forename: O E
authors.initials: OE
authors.lastname: Lipskaia
authors.forename: A S
authors.initials: AS
authors.lastname: Efimov
mesh_terms: D000328:Adult; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D003928:Diabetic Nephropathies / Q000150:complications*; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D008297:Male; D011994:Recombinant Proteins; D006435:Renal Dialysis; D016896:Treatment Outcome
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin